These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 8065591)
21. Transdermal progesterone cream as an alternative progestin in hormone therapy. Leonetti HB; Landes J; Steinberg D; Anasti JN Altern Ther Health Med; 2005; 11(6):36-8. PubMed ID: 16320858 [TBL] [Abstract][Full Text] [Related]
22. [The importance of estradiol treatment by the transdermal route in preventing postmenopausal osteoporosis]. Borrelli AL; Hoffmann M; Pecchillo MA; Iolascon G Clin Ter; 1992 Apr; 140(4):379-82. PubMed ID: 1587121 [TBL] [Abstract][Full Text] [Related]
23. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134 [TBL] [Abstract][Full Text] [Related]
24. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201 [TBL] [Abstract][Full Text] [Related]
25. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Odmark IS; Jonsson B; Bäckström T Am J Obstet Gynecol; 2001 May; 184(6):1131-8. PubMed ID: 11349178 [TBL] [Abstract][Full Text] [Related]
26. [The effects of progestin on the bone metabolism in postmenopausal women]. Ren Y; Zhu G Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):135-7. PubMed ID: 7796643 [TBL] [Abstract][Full Text] [Related]
27. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy]. Ciepłuch R; Czestochowska E Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021 [TBL] [Abstract][Full Text] [Related]
29. Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17beta-estradiol and intermittent medroxyprogesterone acetate. Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A Climacteric; 2003 Sep; 6(3):204-10. PubMed ID: 14567768 [TBL] [Abstract][Full Text] [Related]
30. Circadian serum levels of dehydroepiandrosterone sulphate in postmenopausal asthmatic women before and after long-term hormone replacement. Kos-Kudla B; Ostrowska Z; Marek B; Ciesielska-Kopacz N; Kudla M; Kajdaniuk D; Siemidska L; Strzelczyk J Endocr Regul; 2001 Dec; 35(4):217-22. PubMed ID: 11858769 [TBL] [Abstract][Full Text] [Related]
31. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025 [TBL] [Abstract][Full Text] [Related]
32. [Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women]. Sun A; Lin S; Wei Y Zhonghua Fu Chan Ke Za Zhi; 2001 Jun; 36(6):348-51. PubMed ID: 11783133 [TBL] [Abstract][Full Text] [Related]
33. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and acceptability of transdermal estradiol in the treatment of postmenopausal bone loss. Lo Dico G; Alongi G; Milazzo I; Savatteri L; Durante M; Scuderi G Panminerva Med; 1992; 34(1):35-7. PubMed ID: 1589256 [TBL] [Abstract][Full Text] [Related]
35. [Transdermal estradiol in the prevention of the menopause-induced increase in osteoresorption]. Stĕpán J; Pospíchal J; Formánková J; Rosenová Z; Kanka J; Mensík J; Presl J; Pacovský V Cesk Gynekol; 1989 Aug; 54(7):496-505. PubMed ID: 2805095 [TBL] [Abstract][Full Text] [Related]
36. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Lees B; Stevenson JC Osteoporos Int; 2001; 12(4):251-8. PubMed ID: 11420773 [TBL] [Abstract][Full Text] [Related]
37. Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium. Pansini F; De Paoli D; Albertazzi P; Bonaccorsi G; Campobasso C; Zanotti L; Pisati R; Giulini NA Eur J Obstet Gynecol Reprod Biol; 1996 Sep; 68(1-2):137-41. PubMed ID: 8886696 [TBL] [Abstract][Full Text] [Related]
38. [Transdermal estrogenic therapy in menopause]. Nencioni T; Polvani F; Penotti M; Porcaro E; Barbieri Carones M Minerva Endocrinol; 1989; 14(1):49-52. PubMed ID: 2543896 [TBL] [Abstract][Full Text] [Related]
39. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Williams SR; Frenchek B; Speroff T; Speroff L Am J Obstet Gynecol; 1990 Feb; 162(2):438-46. PubMed ID: 2309827 [TBL] [Abstract][Full Text] [Related]
40. Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology. de Cecco L; Gerbaldo D; Fulcheri E; Ferraiolo A; Baracchini P; Bernardini L; Pescetto G Maturitas; 1992 Dec; 15(3):199-208. PubMed ID: 1334524 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]